Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;40(4):1159-1164.
doi: 10.1007/s12639-014-0641-1. Epub 2015 Jan 22.

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

Saeedeh Farajzadeh  1 , Amireh Heshmatkhah  2 , Behrooz Vares  2 , Elham Mohebbi  3 , Azadeh Mohebbi  2 , Mahin Aflatoonian  2 , Sana Eybpoosh  4 , Iraj Sharifi  1 , Mohammad Reza Aflatoonian  5 , Simin Shamsi Meymandi  1 , Ali Reza Fekri  1 , Mahshid Mostafavi  1
Affiliations

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

Saeedeh Farajzadeh et al. J Parasit Dis. 2016 Dec.

Abstract

Leishmaniasis is a spectrum of disease condition with considerable health impacts, caused by different species of Leishmania. This disease is currently endemic in 98 countries and territories in the world. There are many treatment modalities for cutaneous leishmaniasis. The use of topical terbinafine in the treatment of cutaneous leishmaniasis has recently been considered. Eighty-eight participants more than two years old with proven acute CL by a positive direct smear were randomly allocated to one of the two study arms: first group received meglumine antimoniate (Glucantime) 20 mg/kg/day intramuscular injection (IM) plus a placebo ointment (Mahan Vaseline) for 20 days. The second group received meglumine antimoniate (Glucantime) 20 mg/kg/day IM plus topical terbinafine, for 20 days and were monitored closely by dermatologist during the course of the study. Crude regression analysis showed that there was no significant difference between placebo and intervention group regarding partial or complete treatment (partial treatment: HRcrude = 1.1, CI 95 % = 0.7-1.7; complete treatment: HRcrude = 1.1, CI 95 % = 0.8-1.7). Although, there was no statistically significant different between the two treatment groups, but clinically it seems that the treatment rate in those who receive glucantime plus terbinafine was more effective than the other group. However this rate depended on the type of lesions. As data indicated ulcerated nodules, papules and plaque in experimental group have been completely improved two times faster than placebo group. Ulcerated nodules, nodules and plaque were partially improved faster in those used tebinafine than placebo ointment.

Keywords: Glucantime; Iran; Kerman; Leishmaniasis; Topical terbinafine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The profile of study
See this image and copyright information in PMC

References

    1. Aflatoonian MR, Sharifi I, Hakimi Parizi M, Aflatoonian B, Sharifi M, Khosravi A, Fekri AR, Khamesipour A, Sharifi H. A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in South Eastern Iran. PLoS ONE. 2014;9(2):e89043. doi: 10.1371/journal.pone.0089043. - DOI - PMC - PubMed
    1. Andrade-Neto VV, Cicco NN, Cunha-Junior EF, Canto-Cavalheiro MM, Atella GC, Torres-Santos EC. The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Trop. 2011;119(2–3):194–198. doi: 10.1016/j.actatropica.2011.05.001. - DOI - PubMed
    1. Bahadman KA, Tallab TM (1997) Terbinafin in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 36:54–60 - PubMed
    1. Bahashwan SA. Therapeutic efficacy evaluation of metronidazole and some antifungal agents with meglumine antimoniate on visceral leishmaniasis by real-time light-cycler (LC) PCR in BALB/c mice. Trop J Pharm Res. 2011;10(3):255–263. doi: 10.4314/tjpr.v10i3.2. - DOI
    1. Beach DH, Holtz CG, Anchlwe GE. Eipid of leishmania promastigotes. Parasitol. 1979;65:203–216. doi: 10.2307/3280147. - DOI - PubMed

LinkOut - more resources